JAC © The British Society for Antimicrobial Chemotherapy 2005; all rights reserved
Supplement |
Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide
1 Vicuron Pharmaceuticals, 455 South Gulph Road, King of Prussia, PA; 3 Vicuron Pharmaceuticals, Fremont, CA, USA; 2 Vicuron Pharmaceuticals, Gerenzano, Varese, Italy
* Corresponding author. Tel: +1-610-491-2201; Fax: +1-610-491-2299; Email: thenkel{at}vicuron.com
The selection of a novel weekly dalbavancin dosage regimen was based on pharmacokinetic and pharmacodynamic data from humans and an animal model of infection. The results from the granuloma pouch model of infection suggested that dalbavancin concentrations 
5 mg/L are necessary for extended in vivo activity. Serum bactericidal activity assessments demonstrated that dalbavancin serum concentrations of approximately 20 mg/L were bactericidal upon two-fold dilution. These data, coupled with simulations based on the pharmacokinetic profile derived from a clinical study in healthy volunteers, were used to design the weekly regimen studied in the initial efficacy trial. This efficacy study showed that a two-dose weekly regimen was well tolerated and associated with a higher clinical response rate than the comparator regimens. The data collectively support the further study of dalbavancin as a once-weekly regimen for the treatment of infections caused by Gram-positive bacteria.
Keywords: dosage regimen , pharmacodynamics , Gram-positive bacteria
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Bailey and K. M. Summers Dalbavancin: A new lipoglycopeptide antibiotic Am. J. Health Syst. Pharm., April 1, 2008; 65(7): 599 - 610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Attwood and K. L. LaPlante Telavancin: A novel lipoglycopeptide antimicrobial agent Am. J. Health Syst. Pharm., November 15, 2007; 64(22): 2335 - 2348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Nicolau, H. K. Sun, E. Seltzer, M. Buckwalter, and J. A. Dowell Pharmacokinetics of dalbavancin in plasma and skin blister fluid J. Antimicrob. Chemother., September 1, 2007; 60(3): 681 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. G. Solon, J. A. Dowell, J. Lee, S. P. King, and B. D. Damle Distribution of Radioactivity in Bone and Related Structures following Administration of [14C]Dalbavancin to New Zealand White Rabbits Antimicrob. Agents Chemother., August 1, 2007; 51(8): 3008 - 3010. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. P. Goldstein, D. C. Draghi, D. J. Sheehan, P. Hogan, and D. F. Sahm Bactericidal Activity and Resistance Development Profiling of Dalbavancin Antimicrob. Agents Chemother., April 1, 2007; 51(4): 1150 - 1154. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. N. Jones, H. S. Sader, T. R. Fritsche, P. A. Hogan, and D. J. Sheehan Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program. J. Clin. Microbiol., July 1, 2006; 44(7): 2622 - 2625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Lin, K. Smith, L. M. Ednie, and P. C. Appelbaum Antipneumococcal Activity of Dalbavancin Compared to Other Agents Antimicrob. Agents Chemother., December 1, 2005; 49(12): 5182 - 5184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Buckwalter and J. A. Dowell Population Pharmacokinetic Analysis of Dalbavancin, a Novel Lipoglycopeptide J. Clin. Pharmacol., November 1, 2005; 45(11): 1279 - 1287. [Abstract] [Full Text] [PDF]
|
|